Background: During oocyte maturation in Xenopus, progesterone induces entry into meiosis I, and the M phases of meiosis I and II occur consecutively without an intervening S phase. The mitogen-activated protein (MAP) kinase is activated during meiotic entry, and it has been suggested that the linkage of M phases reflects activation of the MAP kinase pathway and the failure to fully degrade cyclin B during anaphase I. To analyze the function of the MAP kinase pathway in oocyte maturation, we used U0126, a potent inhibitor of MAP kinase kinase, and a constitutively active mutant of the protein kinase p90 Rsk , a MAP kinase target.
Background
A hallmark of the eucaryotic cell cycle is the alternation of S and M phases, even in the simple early embryonic cell cycles that lack G1 and G2 phases. The major exception to this rule occurs in meiosis, when two successive M phases control the reduction divisions of meiosis I and II. The controls that ensure successive meiotic M phases have been studied most extensively in Xenopus oocytes undergoing meiotic maturation. In particular, the activity of the mos proto-oncogene product, a mitogen-activated protein (MAP) kinase kinase kinase, is important for suppression of S phase after meiosis I [1] . Mos is not sufficient, however, because even ectopic overexpression of an active glutathione-Stransferase (GST)-Mos fusion protein is unable to prevent cyclin B degradation and exit from M phase after anaphase I in the presence of cycloheximide [1, 2] . Ordinarily, only 50% of cyclin B is targeted for destruction by the anaphase-promoting complex (APC) during exit from meiosis I, due in part to increased cyclin B synthesis [2] [3] [4] . Changes in the abundance of cyclin B have been correlated with changes in the phosphorylation state and electrophoretic mobility of the Cdc27 component of the APC [5] .
MAP kinase activity has also been implicated at two other control points in the oocyte maturation process [6] [7] [8] [9] . In oocytes arrested at the G2-prophase border, progesteronedependent entry into meiosis I is accompanied by the synthesis of Mos [2, 10, 11] . Accumulation of Mos above a threshold level [12] activates a MAP kinase pathway [11, 13, 14] leading to the activation of maturation-promoting factor (MPF), most likely through activation of a target of MAP kinase, p90 Rsk [15] . Activated p90 Rsk inactivates Myt1, a negative regulator of MPF [16] , thereby promoting activation of MPF and entry into meiosis I. The importance of MAP kinase/Rsk activation is suggested by significant inhibition of germinal vesicle breakdown (GVBD) by experimental treatments that block activation of MAP kinase [2, 10, 17, 18] . Moreover, overexpression of Mos, MAP kinase kinase or constitutively activated MAP kinase can induce GVBD in meiosis I in a significant fraction of the oocyte population in the absence of progesterone [19] [20] [21] [22] .
A third control point in oocyte maturation in which MAP kinase has been implicated is in metaphase II arrest at the end of meiosis II. The cytoplasmic activity responsible for metaphase arrest, originally termed cytostatic factor (CSF) by Masui and Markert [23] , is generated by the activated MAP kinase pathway [6] [7] [8] [9] . When assayed in blastomeres of cleaving embryos, expression of either Mos, MAP kinase kinase or thio-phosphorylated MAP kinase is sufficient to cause CSF arrest [9, 19, 24, 25] . More recently, a MAP kinase target, the protein kinase p90 Rsk , was shown to be the sole mediator of CSF arrest: constitutively active Rsk caused CSF arrest in the absence of an active MAP kinase pathway [26] , and depletion of Rsk from egg extracts removed CSF activity, which could be restored by readdition of Rsk [27] .
Studies of the role of Mos and the MAP kinase pathway at various points in the oocyte maturation process have been complicated by the inability to completely inhibit maturation with reagents that inhibit Mos synthesis or block MAP kinase kinase activity. This suggests that a non-MAP kinase pathway might be sufficient to induce maturation in the absence of an active MAP kinase pathway, at least in a sub-population of oocytes. Possible alternative pathways include those mediated by the protein kinase Eg2 [28] , and the polo-like kinase pathway involved in activation of the phosphatase Cdc25C [29] . In this paper, we report the results of studies with U0126, a new, more potent inhibitor of MAP kinase kinase [30] . We found that, in freshly isolated oocytes, the MAP kinase pathway was not required for entry into meiosis I induced by progesterone but was required for S-phase suppression, regulation of cyclin B degradation by the APC, and spindle formation during meiosis II. Moreover, these functions of MAP kinase were mediated solely by p90 Rsk .
Results

U0126 treatment does not block GVBD
Numerous studies have shown that activation of Mos, MAP kinase kinase or MAP kinase is sufficient to induce meiosis I in the absence of progesterone [6] [7] [8] [9] [19] [20] [21] [22] . To address whether MAP kinase activation is necessary throughout the progesterone-dependent meiotic process, U0126, an inhibitor of the MAP kinase kinase MEK1 was used. Because U0126 can inhibit activated MEK1 [30] , it produces more complete inhibition than other drugs such as PD98059, which function only to prevent MEK1 activation. Oocytes were induced to mature using progesterone, in the presence or absence of U0126, and scored as a function of time for GVBD (onset of meiosis I) by the appearance of a white spot. As shown in Figure 1a , 90% of the inhibitor-treated oocytes underwent GVBD, albeit delayed by more than an hour compared with controls. Oocytes at GVBD, in the presence or absence of U0126, were indistinguishable from one another either physically or after cytological analysis (Figure 1b,c) . A similar conclusion was recently reported by Fisher et al. [31] using a less specific inhibitor of MAP kinase activation, geldanamycin.
Inhibitor treatment blocks MAP kinase and p90 Rsk activation but not synthesis of Mos
To confirm that U0126 was blocking the MAP kinase pathway, MAP kinase assays using epidermal growth factor (EGF) receptor peptide as substrate were conducted on control and inhibitor-treated oocyte cytosols at 0 hours and 6 hours after progesterone addition (a time at which both treatment groups had reached maximal GVBD). Figure 2a shows that MAP kinase was dramatically activated in control oocytes at GVBD, but undetectable in resting oocytes or in U0126-treated oocytes at GVBD. Immunoblots for activated MAP kinase (pMAPK), and for p90 Rsk showed that inhibitor treatment completely eliminated phosphorylated (active) MAP kinase immunoreactivity and the mobility shift of p90 Rsk associated with MAP kinase phosphorylation during maturation [32] (Figure 2b ). These two observations show that MAP Research Paper The MAP kinase pathway in meiosis II Gross et al. 431
Figure 1
Effect of U0126 on oocyte maturation. (a) GVBD. Stage VI oocytes were manually dissected from the ovary, cultured in 0.65 × DMEM with 50 µg/ml gentamycin and induced to mature using 100 ng/ml progesterone. Either 50 µM U0126 or DMSO alone (control) was added 1 h before addition of progesterone. Oocytes were scored as a function of time for GVBD (observed as appearance of a distinctive white spot). kinase activity was completely inhibited by U0126. Interestingly, although it was previously demonstrated that a feedback loop that depends on the MAP kinase pathway contributes to maximal Mos expression [2, 19, 33] , initial Mos accumulation appeared unaffected by inhibitor treatment (Figure 2b ), suggesting that a feedback loop from MPF can lead to Mos accumulation independently of the MAP kinase pathway [3, 19] . To gain a better understanding of MPF activation in the absence of the MAP kinase pathway, the same oocyte extracts were immunoblotted for Cdc25C and Plx1, the Xenopus homolog of the pololike kinase involved in activation of the phosphatase Cdc25C [29] (Figure 2c) . Previous work has shown that activation of Plx1 at GVBD during maturation coincides with an upward mobility shift due to phosphorylation [29] . As shown in Figure 2c , Plx1 underwent a full mobility shift at GVBD in both control and inhibitor-treated oocytes, demonstrating that Plx1 activation does not require the MAP kinase pathway.
Previous results have shown that expression of exogenous Mos or constitutively active Plx1 is sufficient to cause GVBD in the absence of progesterone [2, 21, 34, 35] . Therefore, it was of interest to evaluate whether their ability to cause GVBD relied on activation of the MAP kinase pathway. In the case of Mos, bacterially-expressed GST-Mos was microinjected into stage VI oocytes in the presence and absence of U0126. As shown in Figure 3a , although Mos efficiently induced maturation in control oocytes, treatment with U0126 completely blocked Mosinduced maturation. As expected, no detectable Mosdependent pMAP kinase signal was evident in the presence of the inhibitor, and endogenous Mos synthesis was not stimulated by GST-Mos (Figure 3a) . These results indicate that MEK1 is a required target of Mos for activation of MPF in meiosis I, but do not exclude the possibility that Mos might phosphorylate other substrates as well when it induces maturation directly. If Mos has another essential substrate other than MEK1, it might explain why antisense oligonucleotides against Mos block GVBD [2,9,10] but active Mos required the MAP kinase pathway to elicit GVBD ( Figure 3a) . In contrast to these results, injection of mRNA encoding a constitutively active form of Plx1 induced GVBD and Cdc2 histone H1 kinase activation (Figure 3b ) in the presence of U0126. Thus, it is likely that activation of Plx1 may underlie the mechanism for cyclin B-Cdc2 activation in U0126-treated oocytes at meiosis I in the absence of the MAP kinase pathway ( Figure 1 ). Interestingly, a smaller fraction of Cdc25 became fully activated (shifted) in the inhibitortreated oocytes compared with controls ( Figure 2c ), suggesting at least some dependence on the MAP kinase pathway for full activation of Cdc25C, although neither Plx1 nor its activating kinase xPlkk1 are substrates for MAP kinase [29, 36] . This observation is consistent with previous data showing that inhibition of Plx1 activation does not completely suppress Cdc25C activation [29] .
To assess the activation state of MPF (cyclin B-Cdc2) in the control and inhibitor-treated oocytes, histone H1 kinase assays were performed on extracts of oocytes collected at the indicated times after progesterone addition (Figure 4a ). Histone H1 kinase activity increased during meiosis I in both groups, and assays with p13SUC1 beads confirmed that the increase was due to Cdc2 (Figure 4c ). Histone H1 kinase activation in the U0126-treated oocytes was, however, not as great as in the controls. Moreover, in the inhibitor-treated oocytes, histone H1 kinase activity did not increase for up to 5 hours post-GVBD, when the control oocytes were undergoing meiosis II with elevated histone H1 kinase activity. Previous studies have shown that the meiosis I→II transition is characterized by the degradation of 50% of the cyclin B at anaphase I followed by re-accumulation of cyclin B upon entry into meiosis II [2, 37] . Western blots indicated that the failure to reactivate cyclin B-Cdc2 in the presence of U0126 correlated strongly with the failure to reaccumulate cyclin B (Figure 4b ).
The reduced level of histone H1 kinase activity at GVBD in the presence of U0126 (Figure 4a,c) was not associated with a reduction in the level of cyclins B1 or B2 at GVBD (Figure 4b ) but was consistent with the reduced activation of Cdc25C seen under these conditions (Figure 2c ). If Cdc25C was only partially activated, then it could be predicted that U0126-treated oocytes would have a higher level of Tyr15-phosphorylated Cdc2-cyclin B (pre-MPF) at GVBD than controls. Indeed, immunoblots of control and U0126-treated oocytes revealed a higher level of tyrosine-phosphorylated Cdc2 at GVBD in the presence of the drug (data not shown). The protein kinase that phosphorylates Cdc2 during maturation is Myt1, which is negatively regulated by phosphorylation by both cyclin B-Cdc2 and p90 Rsk [15, 16] . Cdc2-dependent phosphorylation and inactivation of Myt1 is associated with a large decrease in electrophoretic mobility on SDS gels [16] . To assess whether Myt1 regulation is altered in the presence of U0126, mRNA encoding kinase-dead Myt1 was translated in a reticulocyte lysate and injected into oocytes. Following progesterone treatment, with or without U0126, samples of oocytes were analyzed for radiolabeled Myt1 electrophoretic mobility by autoradiography and for the level of phosphorylated Cdc2 by immunoblotting (Figure 4d ). Myt1 inactivation was delayed and the level of phosphorylated Cdc2 persisted longer after progesterone addition during maturation in the presence of U0126. These results could reflect altered activity of both p90 Rsk and cyclin B-Cdc2 but, in any case, they suggest that the reduced Cdc2 histone H1 kinase activity at GVBD in the presence of U0126 (Figure 4a ) is due to both reduced Cdc25C activation (Figure 2c ) and delayed Myt1 inactivation, resulting in a higher level of inactive phosphorylated Cdc2-cyclin B.
Cyclin B degradation is dependent on the activity of a ubiquitin ligase (E3) complex, the APC, in which Cdc27 is a conserved component [38] . In Xenopus, cell-cycle-related changes in APC activity towards cyclin B have been correlated with changes in the electrophoretic mobility of Cdc27 [5] . Western blots from both control and U0126-treated oocytes demonstrate that Cdc27 undergoes a mobility shift upwards, shortly after the onset of GVBD, a time that coincides with anaphase I and cyclin B degradation (Figure 4b,c) . This shift has previously been demonstrated to correlate with activation of the APC [5] . At 4 hours after GVBD, however, when control oocytes enter metaphase II, Cdc27 is further shifted in control but not in U0126-treated oocytes (Figure 4b,c) . This second mobility shift has been reported to correlate with cyclin B2 stabilization in Xenopus extracts [5] , possibly reflecting inhibition of ubiquitination. The absence of hypershifted Cdc27 and a reduced level of cyclin B2 in U0126-treated oocytes 4-5 hours after GVBD (Figure 4b) suggests that, in the absence of the MAP kinase pathway, cyclin B is rapidly degraded because of higher activity of the APC. To assess 
this possibility directly, 35 S-methionine-labeled cyclin B1 synthesized in a reticulocyte lysate was injected into oocytes 4 hours after GVBD in the absence and presence of U0126. Cyclin B1 was chosen because of previous evidence that its degradation by the APC does not require binding to Cdc2 [39] . As shown in Figure 5 , in controls with an active MAP kinase pathway, cyclin B1 had a halflife of much greater than 30 minutes. In the presence of U0126, however, the half-life decreased dramatically to less than 15 minutes. These changes in stability were associated with the expected changes in mobility of Cdc27. Cyclin B1 lacking the destruction box that targets it for APC-mediated degradation was not degraded in the presence or absence of U0126 (Figure 5a ). These results indicate the MAP kinase pathway increases the level of cyclin B in meiosis II by inhibiting APC-mediated degradation.
U0126 treatment induces DNA replication after meiosis I
We analyzed whether U0126-treated oocytes (Figure 4 ) remained in M phase after meiosis I or were instead forming nuclei, entering S phase, and undergoing DNA replication in a manner similar to that previously reported for maturing oocytes after cycloheximide treatment or after inhibition of Mos during the meiosis I→II transition [1, 2] . Cytological analysis indicated that meiosis I spindles cannot be detected after GVBD (data not shown). Instead, as shown in Figure 6 , both the U0126-and cycloheximide-treated oocytes underwent DNA replication after GVBD, a process that requires assembly of a nuclear envelope [40] . Aphidicolin treatment of the U0126-treated oocytes completely abolished dCTP incorporation, indicating that DNA replication rather than DNA repair was occurring. Entry into meiosis II and suppression of DNA replication have been shown to be dependent on the synthesis of both Mos and cyclin B [1, 2] . Our experiments suggest that the requirement for Mos to suppress DNA synthesis is mediated exclusively by MAP kinase activation. The fact that in U0126-treated oocytes the APC remains active for cyclin B degradation ( Figure 5 ) may in part account for M-phase exit.
The protein kinase p90 Rsk is a proximal target of MAP kinase that becomes fully activated during oocyte maturation [32] . We previously reported the generation of a constitutively active form of p90 Rsk that also exhibits elevated specific activity at GVBD compared with wild-type p90 Rsk [26] . Because p90 Rsk is the downstream substrate for MAP kinase sufficient to account for MAP kinase-dependent metaphase arrest (CSF arrest) at the end of meiosis II [26, 27] , we assessed the effect of expression of activated p90 Rsk on entry into meiosis II in the presence of U0126. As shown in Figure 7 , expression of constitutively active Rsk but not β-galactosidase restored the Cdc27 hypershift and the elevated level of cyclin B2 indicative of meiosis II. Moreover, U0126-treated oocytes expressing constitutively active Rsk were found to contain metaphase spindles characteristic of meiosis II (Figure 7b ), whereas none were found in those treated with U0126 (data not shown), which were synthesizing DNA ( Figure 6 ). The results indicate that the sole target of MAP kinase required for regulation of events in meiosis II is p90 Rsk .
Discussion
Numerous studies have demonstrated that activation of the MAP kinase pathway is sufficient to induce maturation in oocytes. Until now, however, it has not been clear whether MAP kinase is necessary for this process. Early work showed that injection of antisense oligonucleotides against Mos blocks MPF activation and GVBD in 60-70% of oocytes [10] . More recently, injection of MEK antibodies into Xenopus oocytes has been reported to significantly block MAP kinase activation and the subsequent activation of MPF and induction of maturation [17] . In addition, overexpression of MKP-1, the MAP kinase superfamily-specific phosphatase, has been shown to block MAP kinase and MPF activation, and Mos accumulation and maturation [19] . Nevertheless, as initially reported by others, in all of these studies the fraction of the oocyte population sensitive to inhibitors of the MAP kinase pathway varies [9] . In our hands, oocytes incubated overnight before use mature more slowly in response to progesterone, require a higher concentration of progesterone and are more sensitive to inhibition of the MAP kinase pathway. The results presented here were conducted with freshly isolated oocytes in which inhibition of the MAP kinase pathway only altered the kinetics rather than the extent of maturation (Figure 1) . Similarly, overexpression of a kinase-inactive mutant of Raf-1 causes only slightly slower kinetics and a reduced percentage of progesterone-induced GVBD due to the absence of MAP kinase activity [41] . Together, these results suggest that an alternative, MAP-kinase-independent pathway may exist to initiate MPF activation in response to progesterone. A similar conclusion was recently reported by Fisher et al. [31] using a different inhibitor to block MAP kinase activation. Our results
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Figure 5
Cyclin B1 degradation in control and U0126-treated oocytes. Control and U0126-treated oocytes were induced to enter GVBD by treatment with progesterone. Oocytes were collected 4 h after GVBD, pre-incubated 15 min in medium plus 10 mM chlorobutanol and injected with 50 nl [ 35 S]methionine-labeled cyclin B1 or ∆N cyclin B1 translated in a reticulocyte lysate as described in the Materials and methods. (a) Oocytes were homogenized at the indicated times and samples were electrophoresed on 10% gels and either processed for autoradiography (upper two panels) or transferred to nitrocellulose and probed with anti-Cdc27 antibodies (lower panel). indicate that the progesterone-dependent, MAP kinaseindependent pathway leading to MPF activation and meiosis I (Figures 1, 2 and 8) is the Plx1 kinase cascade.
MAP kinase does, however, appear to be required for meiosis II, in that, after GVBD, U0126-treated oocytes exited meiosis and soon thereafter initiated DNA replication instead of meiosis II. In addition, in these oocytes, Cdc27 did not become hyperphosphorylated and direct injection of radiolabeled cyclin B indicated that the APC was more active in the absence of MAP kinase ( Figure 5 ). Our results support the earlier evidence [5] that changes in the mobility of Cdc27 are accurate reflections of APC activity in oocytes. Cycloheximide treatment of GVBD oocytes also blocks meiosis II and induces DNA replication, an effect that may be linked to reduction of Mos and cyclin B levels, as previously reported [1, 2] . U0126 treatment does not prevent Mos accumulation but does prevent increased MAP kinase activity, accumulation of cyclin B after meiosis I, and the corresponding increase in histone H1 kinase activity essential for meiosis II and arrest at second meiotic metaphase (Figures 2 and 4) . This suggests that MAP kinase is required after GVBD for accumulation of cyclin B to a level that ensures S phase is not induced after anaphase I. This reflects effects of the MAP kinase pathway in meiosis II on cyclin B degradation by the APC (Figure 5 ). At present, the data cannot distinguish between a direct effect of the MAP kinase pathway/p90 Rsk on the APC itself versus an effect on a possible inhibitor of the APC [5] . Although a detectable level of cyclin B was present in S-phase oocytes after U0126 treatment, histone H1 kinase activity was low ( Figure 4 ) and Cdc2 was predominantly in the inactive tyrosine-phosphorylated state. This suggests that the 'threshold level' of cyclin B-Cdc2 activity needed to define a G2/M cell [42] requires the reaccumulation of cyclin B to the higher level afforded by an active MAP kinase pathway.
An activated form of the MAP kinase substrate p90 Rsk was able to promote reaccumulation of cyclin B, Cdc27 hyperphosphorylation and spindle formation, suggesting that it is directly capable of controlling these events. As constitutively active Rsk produced these effects in the presence of U0126, Rsk is the sole substrate of MAP kinase required for these effects. Whether Rsk acts directly or indirectly on the APC or also on cyclin B synthesis remains to be determined. Nevertheless, combined with the previous evidence that p90 Rsk activation is necessary and sufficient to explain MAP-kinase-dependent arrest at metaphase II (CSF arrest) [26, 27] , these results indicate that Rsk is sufficient at multiple points in meiosis II to execute the functions of the MAP kinase pathway.
Materials and methods
Oocyte injection and treatments
X. laevis females were obtained from Xenopus I and primed with 35 I.U. pregnant mare's serum gonadotropin 3-5 days before manual dissection U0126 treatment induces DNA replication in post-meiosis I oocytes. Control oocytes and oocytes pretreated with 50 µM U0126 for 1 h (lanes 6-9) were injected with 50 nl [α-32 P]dCTP (3000 Ci/mmol; 10 µCi/µl) and maturation induced using 100 ng/ml progesterone. Control oocytes were collected 3 h after injection (before GVBD had occurred, lane 1), and 2 h and 4 h after GVBD (lanes 2,3). Some oocytes were transferred into medium containing 100 µg/ml cycloheximide (CHX) 30-60 min after GVBD (lanes 4,5). Aphidicolin (APD, 20 µg/ml) was added to some U0126-treated oocytes within 15 min after GVBD (lanes 8,9). Oocytes were collected at the indicated times after the corresponding treatments (lanes 4-9), followed by lysis, proteinase K treatment and extraction of the DNA [1] . DNA corresponding to three oocytes was loaded on a 0.9% agarose gel, electrophoresed and processed for autoradiography.
Figure 7
Rsk mediates effects of the MAP kinase pathway on the meiosis I to II transition. (a) Uninjected oocytes, or oocytes expressing either a constitutively active form [26] of p90 Rsk (CA-Rsk) or β-galactosidase (β-gal), were treated with progesterone in the presence or absence of U0126. At GVBD and 4 h later, at metaphase II (MII), oocytes were collected and immunoblotted for the level of cyclin B2 and the mobility of Cdc27. (b) Control oocytes or U0126-treated oocytes injected with mRNA encoding CA-Rsk were analyzed for metaphase spindles. No spindles were formed in oocytes treated with U0126 alone that were synthesizing DNA ( Figure 6 ). Similar results were obtained in 10 independent analyses. of oocytes from excised ovary fragments. Injection of oocytes and induction of maturation by progesterone (100 ng/ml) were as described previously [26] . Extraction of oocytes and assays for histone H1 kinase activity or MAP kinase activity are described elsewhere [2, 43] . Immunoblotting procedures and the antibodies used to follow cyclin B, Mos, Rsk, activated MAP kinase and Cdc27 have also been described elsewhere [2, 26, 32, 44] . U0126 was obtained from Promega and dissolved in DMSO before addition to a final concentration of 50 µM. The control oocyte population was treated with DMSO alone. U0126 was generally present for 1 h before progesterone addition. The mRNA encoding constitutively active Rsk or β-galactosidase was prepared with a mMessage mMachine kit (Ambion) as described [26] and injected in 30 nl volumes into oocytes at a concentration of 1.0 mg/ml. The cDNA encoding cyclin B1 lacking the destruction box by deletion of sequence encoding amino acids 1-44 (∆N-cyclin B1) was generated by PCR using the primers 5′-GACGACGACAAGATGGCAGAGGTGAAAGTG-3′ and 5′-GAGGA-GAAGCCCGTTCACATGAGTGGGCGGGC-3′ and Xenopus cyclin B1 in pET3 as template. The amplified fragment was cloned into cCITE-LIC vector according to the manufacturer's protocol (Novagen). The Myt1 cDNA (kind gift of A. Nebreda, [15] ) was cloned into the pET30-4C vector and Asn231 was then changed to Ala using the Quickchange procedure (Stratagene) to create a kinase-dead mutant. Cyclin B in pET3 vector, ∆N-cyclin B1 in pCITE vector, and Myt1 N/A in pET30 vector were translated in a reticulocyte lysate (TnT7 Quick Transcription Translation System, Promega) in the presence of [ 35 S]methionine (ICN). Unincorporated [ 35 S]methionine was removed with a Vivaspin filter unit (ISC BioExpress) and the radiolabeled proteins equilibrated with injection buffer (20 mM Hepes, pH 7.5, 88 mM NaCl, 7.5 mM MgCl 2 , 10 mM β-mercaptoethanol). For experiments studying the degradation of 35 S-cyclin B, oocytes were induced to enter GVBD by treatment with progesterone (100 ng/ml). To prevent parthenogenetic activation by the microinjection pipet, 4 h after GVBD, oocytes were incubated in medium containing 10 mM chlorobutanol for 10 min before injection, during the injection, and after injection of 50 nl 35 S-labeled cyclin B1 or ∆N-cyclin B1. Oocytes were collected and homogenized in EB (80 mM β-glycerophosphate, 20n mM EGTA, 15 mM MgCl 2 , 1 mM DTT, 1 × protease inhibitor cocktail (Complete, Roche)) at the indicated times after injection and analyzed by SDS-PAGE and autoradiography. 35 S-Myt1 was injected into resting oocytes that were then treated with progesterone (100 ng/ml) to induce GVBD. Oocytes were collected and homogenized in EB at the indicated times and analyzed by SDS-PAGE and autoradiography. Bacterially expressed GST-Mos was prepared as described previously [2] . For DNA synthesis measurements, [α-32 P]dCTP (3000 Ci/mmol, 10 mCi/ml) was injected just before progesterone treatment. For analysis, oocytes were lysed, treated with proteinase K, extracted with phenol/chloroform, and analyzed by agarose gel chromatography and autoradiography as described [1] . Where used, aphidicolin (20 µg/ml) was added to the medium within 15 min of GVBD, before detectable DNA synthesis occurred in controls. Confocal analysis of oocytes and staining for metaphase spindles was carried out as previously described [26] .
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